Management of restless legs syndrome in chronic liver disease: A challenge for the correct diagnosis and therapy

Table 6 Results for pramipexole therapy during follow-up of 170 patients

Test (range)	135th day	165th day	205th day
Hamilton rating scale (0-66)	9.2 ± 0.1	8.7 ± 1.3	9.0 ± 1.1
	(-9.3 ± 3.0; < 0.01)	(-9.8 ± 1.7; < 0.01)	(-9.5 ± 0.2; < 0.01)
PSQI (0-5)	2.2 ± 0.7	1.9 ± 0.7	2.3 ± 0.7
	(-1.2 ± 0.2; < 0.05)	(-1.32 ± 0.2; < 0.05)	(-1.1 ± 0.2; < 0.05)
ESS (0-24)	8. 3 ± 0.7	8. 5 ± 0.4	8 .7 ± 1.1
	(-7.1 ± 0.4; < 0.01)	(-7.3 ± 0.7; < 0.01)	(-7.7 ± 0.2; < 0.01)
IRSL (0-40)	0-10 (mild) = 51	134	110
	11-20 (moderate) = 100	12	45
	21-30 (severe) = 19	14	15
	31-40 (very severe) = 0	0	0

Within-group analysis was done by comparing results at each day’s visit vs baseline. ESS: Excessive diurnal sleepiness; IRLS: International RLS severity scoring system; PSQI: Depression, sleep quality assessment.